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Abstract
Background: People with a melanoma diagnosis are at risk of recurrence, developing a new primary or
experiencing disease progression. Previous studies have suggested that fear of a cancer recurrence is clinically
relevant in this group of patients and, if not addressed, can lead to distress. Mindfulness-based interventions have
been shown to alleviate symptoms of anxiety and depression among various groups of cancer patients. Online
mindfulness-based interventions have the potential to reach people unable to attend face-to-face interventions due
to limitations such as cancer-related illness, transportation or time constraints. This study aims to (1) examine
whether individuals with a melanoma diagnosis are willing to participate and adhere to a 6-week online
mindfulness-based intervention and (2) explore potential benefits of the program on fear of cancer recurrence,
worries, rumination, perceived stress and trait mindfulness to inform the design of a clinical trial.
Methods/design: This is a single-site randomised controlled trial of a feasibility study. Seventy-five participants with
stage 2c or 3 melanoma will be recruited from a melanoma outpatient clinic and randomised (2:1) either to an
online mindfulness-based program (intervention) or to usual care (control). The intervention is a 6-week program
specifically developed for this study. It consists of videos describing the concept of mindfulness, short daily guided
meditation practices (5–10 min), automated meditation reminders and instructions for applying mindfulness in daily
life to enhance wellbeing. All participants will complete questionnaires at baseline and at 6-week post-
randomisation. Participants in the control group will be given access to the online program at the end of the study.
Primary outcomes are overall recruitment; retention; extent of questionnaire completion; and usability and
acceptability of, and adherence to, the program. The secondary outcomes are fear of cancer recurrence, worries,
rumination, perceived stress and trait mindfulness measured using validated instruments.
Discussion: This feasibility study will evaluate participants’ satisfaction with the program and identify barriers to
recruitment and adherence. The recruitment and data collection process will highlight methodological aspects to
address in the planning of a larger scale study assessing the impact of an online mindfulness-based intervention on
fear of cancer recurrence and wellbeing.
Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12617000081314. Registered on 16 January 2017.
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Background
Melanoma affects over 232,000 people worldwide each
year [1]. People who have received treatment for melan-
oma are up to nine times more likely to develop a new
melanoma, and this risk remains elevated for more than
20 years after the initial diagnosis [2]. The risk that the
melanoma comes back locally or in another part of the
body after it has been treated (i.e. recurrence) is related
to the clinical characteristics of the tumour (i.e. thick-
ness, ulceration and spread) and is estimated overall to
be 9% [2]. Thick primaries, ulcerated lesions or regional
lymph node metastases, corresponding to stages 2b, 2c,
3 or 4 according to the melanoma TNM staging system
[3], have a high risk of relapse with 5-year mortality
rates of 20–80% [3].
Fears and concerns about a melanoma recurrence are
common among melanoma survivors. In a large multi-
centre study examining the supportive care needs, anx-
iety, depression and quality of life among patients
diagnosed with melanoma, the main concerns were the
risk of recurrence (17%), fear of metastatic disease (17%)
and uncertainty regarding outcomes if metastatic disease
is detected (16%) [4]. Furthermore, a high proportion
(72%) of melanoma survivors with a history of at least
one diagnosis of melanoma reported clinically relevant
fear of cancer recurrence (FCR) [5].
FCR is a rational and normal response to a stressful
event, but if the fear persists and is not resolved through
coping or adaptation, it may lead to psychological dis-
tress such as anxiety or depression [6]. In patients with
melanoma, psychological distress is associated with delay
in seeking medical advice [7] and poor psychological ad-
justment, which is related to disease progression through
immunological response to stress [8].
FCR is often viewed as a multidimensional phenomenon,
with an emotional component of anxiety and cognitive as-
pects of worry, preoccupation and intrusive thoughts [9].
Maladaptive information processing styles, such as worry-
ing or ruminating uncontrollably over cancer-related infor-
mation, were positively correlated with FCR [10]. A
theoretical formulation of FCR, proposed by Fardell and
colleagues, suggests that attentional bias towards worri-
some and unhelpful thoughts underlies the association be-
tween maladaptive information processing and FCR [11].
According to this formulation, teaching skills to cultivate
attentional flexibility and mindful awareness of thoughts
could have therapeutic benefits [11]. These skills are at the
core of mindfulness-based interventions [12].
Mindfulness is a state of mind in which one pays at-
tention to the present moment in a non-judgmental,
curious, accepting and decentred way [12–14]. In this
state, thoughts and feelings are observed as temporary
events in the mind, instead of a reflection of oneself or
reality. Through detached self-observation, individuals
learn to reflect on situations and are able to respond in
more adaptive ways instead of reacting in an automatic,
habitual pattern [12]. Hence, the practice of observing
one’s thoughts, emotions and body sensations, with dis-
cernment rather than judgment, is believed to be a start-
ing point linking mindfulness practice and psychological
wellbeing [15, 16]. Supporting this idea, a meta-analysis
exploring the mechanisms underlying the therapeutic ef-
fects of mindfulness-based interventions (MBIs) on psy-
chological outcomes demonstrated that mindfulness
positively mediates the effects of the interventions on
mental health outcomes, such as depression, stress and
anxiety, while rumination and worry negatively mediate
these same outcomes [17].
In MBIs, the cultivation of mindfulness is practised in
two distinct and concurrent ways, namely formal and in-
formal practices. The formal practice of mindfulness
meditation can be done in different ways (e.g. walking,
movement, sitting) [12, 18, 19]. These practices strengthen
attention regulation and allow observation of mental
habits such as rumination [18, 19]. As the practice evolves,
the meditator gains clarity of mind and greater awareness
of his or her mental and emotional fluctuations, enabling
them to alter reactive cognitive and emotional habits re-
lated to mental distress [20].
Through informal practice, the individual is encour-
aged to bring a similar approach of awareness to daily
activities. Paying attention to the sensory experience
of each moment keeps the attention more in the
present moment and reduces worry and rumination
[12]. Regular meditation builds the attention founda-
tion for informal practice, and together they lead to
increased mindfulness in everyday life [21, 22].
In oncology settings, a meta-analysis of 22 studies on
patients with different cancer types and stages reported
moderate benefits of MBIs in reducing symptoms of
anxiety and depression [23]. A recent trial demonstrated
the efficacy of a MBI in assisting breast cancer survivors
to cope with their fear of recurrence [24], with partici-
pants randomly assigned to a 6-week MBI showing sig-
nificant improvements in FCR.
Besides the growing body of evidence on the benefits
of MBI for individuals living with cancer, practical bar-
riers exist that may diminish access to, and participation
in, face-to-face programs. Generally, online interventions
are more easily accessible, are available at any time to
people in their own environment, and enable people to
work at their own pace and to remain anonymous. In
addition, online MBIs are less costly because they do not
necessarily require the involvement of a trained therapist
educated in mindfulness [25–27]. In a cross-sectional
survey of 291 individuals attending a melanoma clinic,
44% of the participants reported interest in participating
in an online meditation-based program, indicating that
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this type of intervention might be acceptable in a similar
cohort [28]. An online Mindfulness-Based Cancer
Recovery program initially tested for feasibility with dis-
tressed participants completing treatment for different
types of cancer showed positive effects on mood disturb-
ance, stress symptoms, spirituality and mindfully acting
with awareness [29].
The current study will assess the feasibility of deliver-
ing an online mindfulness-based program to patients af-
fected by melanoma. It will examine patterns of usage
and content relevance to inform the design of a larger
randomised control trial.
Aims and objectives
The overall aim of the study is to examine the feasibility
and acceptability of an online mindfulness-based pro-
gram among people who have completed treatment for
melanoma.
The primary objective of the study will be to assess the
feasibility of conducting a larger scale randomised con-
trol trial by evaluating:
– Overall recruitment, retention and questionnaire
completion rates
– Adherence to, and usability and acceptability of, the
online program
The secondary objectives will be to assess the potential
benefit of the intervention on fear of cancer recurrence,
worry, rumination, perceived stress and trait mindfulness
compared to a usual-care group and to provide effect
size and variance estimates for these outcomes to inform
the design of a larger clinical trial.
Methods/design
Design
The development of the study protocol followed the
SPIRIT (Standard Protocol Items: Recommendations for
Interventional Trials) guidelines [30] (Additional file 1).
The description of the intervention followed the TIDieR
(Template for Intervention Description and Replication)
guidelines [31] (Additional file 2).
This study is a single-centre, randomised controlled
pilot study. The control group will continue to receive
care from their treatment centre as usual, while partici-
pants in the intervention group will receive access to a
6-week online mindfulness program as well as their
usual care. The groups will be compared to assess the
potential effect of the intervention on a series of out-
come measures. Measurements will take place at base-
line (i.e. before randomisation) and at the end of the
study (i.e. 6 weeks after randomisation). In the interven-
tion group, participant engagement with, and usability
and acceptability of, the program will be assessed weekly
through a short questionnaire. The overall design and
participant flow through the trial is illustrated in Fig. 1.
Clearance to conduct this study was granted by the hu-
man research ethics committees of the recruitment centre
(HREC/16/PMCC/139) on 4 January 2017 and by Deakin
University (DUHREC 2017-036) on 6 February 2017.
Eligibility criteria
Participants will be included if they have a melanoma
diagnosis of stage 2c, 3a, 3b or 3c and completed their
last treatment within the past 5 years, are 18 years or
older, have sufficient understanding of English to con-
sent and participate, and have access to the Internet.
Patients with a history of distant metastasis will be ex-
cluded as the disease trajectory of stage 4 melanoma re-
mains unpredictable and generally incurable when
compared to other stages with high risk of recurrence
[32, 33]. Patients will also be excluded if they have a se-
vere cognitive impairment or intellectual disability, as re-
ported in the medical record or determined by the
treating clinician or oncology nurse, or are due to com-
mence or currently receiving treatment for a melanoma
recurrence or a second melanoma.
Setting and recruitment process
Recruitment will take place in the melanoma outpatient
clinics of a major metropolitan cancer centre in
Melbourne, Australia. Patients will be identified through
the melanoma outpatient database and study eligibility
determined using electronic medical records.
During the follow-up consultation, clinicians will in-
form patients of their eligibility and will invite them to
meet with the researcher at the end of the consultation
to learn more about the study.
Patients will be reminded that participation is volun-
tary and their decision to participate or not will have no
impact on their clinical care. A patient information
package will be provided to each interested patient, and
the researcher will follow up by telephone as agreed with
patients to answer any questions related to the project.
Upon providing online consent to participate, a unique
study identification number will be automatically gener-
ated for each participant. This identification number will
be generated by a SSL-certified server to ensure privacy
and integrity of the data and will not contain partici-
pants’ personal information. Participants will then be di-
rected to the baseline questionnaire and upon
completion will be randomised into either the interven-
tion or the control group. Participants will also receive
an email confirming the condition they are assigned to.
The email for the intervention group will also comprise
a URL address including the unique study identification
number to access the intervention.
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Randomisation
Participants are randomised (2:1) to the intervention or
control group stratified by sex, time since treatment
completion (≤12 months, >12 months), and meditation
experience (yes/no). A random sequence will be gener-
ated for each one of the eight strata using block ran-
domisation. For every three participants enrolled in each
stratum, two will be allocated to the intervention group
and one to the control group. Random sequences will be
embedded in the online system, ensuring allocation con-
cealment. Study personnel will not have access to the se-
quences and will be blind to group assignment. After
randomisation, participants will be unblinded to group
assignment, as the intervention does not allow for blind-
ing. All questionnaires will be completed online, which
will reduce the influence of researcher bias. Given the
nature of the intervention and the context in which
participants are recruited, i.e. outpatient clinic, we can-
not rule out the usual risks of bias due to participants
not being blinded to treatment allocation. However, in
this study, all surveys will be completed online; health
practitioners have no involvement in the collection or
assessment of any of the trial outcomes. Unequal ran-
domisation, where the number of participants allocated
to the intervention group exceeds that in the control
group, has been identified as a suitable approach in
early-phase studies where the aim is to explore various
dimensions of the intervention, such as patterns and fre-
quencies of usage [34].
Intervention group—online mindfulness-based program
The intervention was developed for the purpose of this
study by the authors, including a clinical psychologist
(RC) with expertise in delivering mindfulness-based pro-
grams (e.g. [35]), cancer nurses and researchers (AU,
LO, DM, MK and PL) with expertise in developing and
evaluating cancer supportive care interventions (e.g.
[36–38]), and a psychology researcher (DA) and website
developer (EO) with expertise in developing and evaluat-
ing online interventions (e.g. [39]). The website content
was initially developed by two of the authors (RC and
LR) and finalised by consensus.
The intervention is a 6-week online mindfulness-based
program designed to (1) help patients understand the
potential benefits of using mindfulness in their day-to-
day life and (2) support the establishment of daily medi-
tation practice. Each week of the program explores a dif-
ferent topic, which builds on the topics explored in
former weeks.
The program includes three weekly components: (1)
an educational component to increase participants’
knowledge about the meaning of mindfulness, its appli-
cation in everyday life and potential benefits; (2) a for-
mal meditation practice to strengthen attention
regulation and learn to observe mental habits such as
rumination or worry; (3) an informal practice to encour-
age participants to integrate mindfulness into their daily
activities. Table 1 describes these components in further
detail.
Participants will receive an automatically generated
email at the end of each week with a link to a brief ques-
tionnaire inquiring about their level of engagement with
the program. Following completion of the questionnaire,
participants will be directed to the website. Each topic of
the program is explained through a short video ranging
from 25 s to 3 min. The script of the videos is available
Fig. 1 Participant flow diagram and recruitment estimates
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for downloading and printing in PDF format so that par-
ticipants can keep a copy of it should they wish to use it
at a later stage. At the end of each video, participants
will be reminded to continue with their daily meditation
practice (formal practice) and will be given a specific
mindfulness task to practise during their daily activities
(informal practice).
To support participants with establishing a meditation
routine, emails containing a link to a short, guided medi-
tation audio file, voiced by co-author RC, will be sent
twice daily. These emails will serve as reminders to
meditate and will provide easy access to the meditation
practice of the week.
The website has a section addressing common ques-
tions about meditation, which is available at any time
throughout the course of the program. The development
of this section was informed by (1) answers to a survey
conducted in a similar study population about the
practice of meditation [28] and (2) questions raised by par-
ticipants of a commercially available meditation-based
program designed for new meditators in the general
population [40].
Participants will have access to the mindfulness pro-
gram at any time every day of the week via the hyperlink
sent in the emails.
Control group—usual care
Participants in the control group will continue to receive
their usual care. They will complete baseline and post-6-
week assessments. Upon completion of the final assessment,
the control group will be offered the online mindfulness
program.
Study discontinuation
Reasons for which participants may wish to discontinue
the program may be varied, e.g. lack of time, lost interest
in the program, or feeling too unwell. Participants who
wish to discontinue will be invited to voluntarily inform
the study team by email and provide reasons for discon-
tinuation. Due to the self-guided, anonymous and auto-
mated nature of the intervention, the study team will
not be able to initiate communication with participants
who ceased interacting with the website.
Data collection
Figure 2 illustrates the overall schedule and time com-
mitment for trial participants in both groups.
All assessments will be performed online through the
Qualtrics platform. At baseline, participants’ demographic
information (i.e. sex, age, education, marital status and
current employment status), previous meditation experi-
ence and preferred time to receive email reminders will be
obtained. Clinical information (i.e. stage of melanoma,
dates of diagnosis and treatment, types of treatment
received and time since the end of treatment) will be col-
lected from medical records, with participants’ consent.
In order to retain patients’ anonymity, all data will be
non-identifiable and stored in password-protected,
encrypted files at Deakin University.
Outcome measures
Fear of Cancer Recurrence Inventory
This 42-item Fear of Cancer Recurrence Inventory
(FCRI) questionnaire is a multidimensional FCR scale
intended for use with all cancer patients. Items were de-
veloped on the basis of a cognitive–behavioural formula-
tion of FCR [41]. The FCRI consists of seven domains:
triggers, severity, psychological distress, functional im-
pairment, reassurance, insight and coping strategies. It
has shown high internal consistency and good construct
and criterion validity in a group of adults with different
cancer types [42] and in adults with a history of melan-
oma [5].
Rumination/Reflection Questionnaire – Rumination subscale
Ruminative thoughts are measured using the 12-item
Rumination subscale that measures “ruminative self-
attention”, the tendency to dwell on, rehash or re-
evaluate events or experiences [43]. Items are rated on a
5-point Likert scale from “strongly disagree” (1) to
“strongly agree” (5). The scale showed good internal reli-
ability in a sample of newly diagnosed colon cancer pa-
tients and mixed cancer patients (Cronbach’s α = 0.90
and 0.92, respectively) [44, 45]. In a sample of women
post-cancer treatment, where a majority were breast
cancer patients, Rumination/Reflection Questionnaire –
Rumination subscale (RRQ-Rum) scores were negatively
correlated with mindfulness change scores (r = −0.34,
P = 0.03) [46].
Penn State Worry Questionnaire – Abbreviated
Worries are measured using the Penn State Worry
Questionnaire – Abbreviated (PSWQ-A), an eight-item
scale [47] adapted from the PSWQ that assesses trait
worry by capturing the excessiveness, prevalence and
uncontrollability of clinical worry [48]. Items on the
PSWQ-A are rated from 1 (not at all) to 5 (very typical),
and total scores range from 8 to 40, with higher scores
indicating greater worry. The PSWQ-A is a valid and re-
liable measure for use among older adults [47] and
women with cancer [49] with internal consistency of 0.
87 and 0.96, respectively.
Cognitive and Affective Mindfulness Scale – Revised
Trait mindfulness is measured using the Cognitive and
Affective Mindfulness Scale – Revised (CAMS-R), a 10-
item self-report questionnaire. This scale uses everyday
language appropriate for those with little meditation
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experience and is designed to capture mindfulness as a gen-
eral daily experience [50]. The questionnaire comprises four
domains of mindfulness (attention, present-focus,
awareness and acceptance/non-judgment). Participants
are asked to rate on a 4-point Likert scale how much
they relate to each statement. Possible responses are
1 = rarely/not at all, 2 = sometimes, 3 = often and 4 =
almost always.
Compared to other measures of mindfulness, the
CAMS-R is unique in that it is related to psychological
distress [51], which is highly relevant to the current
study population [52].
Perceived Stress Scale
The Perceived Stress Scale (PSS; 10-item version) is a
self-report questionnaire measuring the global percep-
tion of stress [53]. The items were designed to evaluate
how unpredictable, uncontrollable and overloaded re-
spondents find their lives. The scale has internal
consistency ranging from 0.75 to 0.86 [54]. Consistent
with this range, studies measuring perception of stress
in people with prostate cancer [55] and breast cancer
[56] had Cronbach’s α of 0.78 and 0.87, respectively.
Assessment of intervention content relevance
At the end of each week, a short questionnaire will ask
participants if the weekly topic was beneficial and what
aspects of the program were liked or disliked. At week 6,
additional three questions ask about the overall helpful-
ness of the mindfulness program and feature that were
the most liked or disliked.
Adherence tracking and meditation log
Google Analytics will be used to track participants’ on-
line activity, including login date/times, navigation pat-
terns, page views and duration, and features used (video,
audio and document downloads). At the end of each
week, a set of three questions will capture information
on any use of other types of meditation unrelated to the
intervention, and frequency and duration of practice.
Another three questions will estimate the amount of in-
formal practice over the past week, and the specific use
of the weekly topic, using a 5-point Likert scale.
Fig. 2 Overall schedule and time commitment for trial participants
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Controlling for existing mindfulness experience in the
control group
In order to control for the potential influence of an ex-
ternal mindfulness-based program in the control group,
participants will answer a question included in the end-of-
study questionnaire about whether they have enrolled in a
mindfulness-based program during the past 6 weeks.
Sample size
We aim to enrol 75 participants over a 5-month period.
The target sample size of 75 participants (50 in the
intervention group, 25 in the control group) meets rec-
ommendations for pilot studies aimed at evaluating
feasibility and estimating variance to inform sample size
and power calculations for a main trial [57]. The 5-
month recruitment period was informed by (1) screening
past melanoma clinic lists for eligible patients at the can-
cer centre over a period of 3 months, (2) findings from a
survey-based study among people with melanoma [28],
and (3) an estimated 70% participation rate based on
findings from online mindfulness-based pilot studies for
patients with cancer [29, 58] (Fig. 1).
Analysis plan
Descriptive statistics will be used to present participants’
characteristics. Demographic and clinical characteristics,
and experience with meditation will be compared be-
tween intervention and control groups, using t test or
Wilcoxon rank-test (for continuous variables) depending
on the outcome distribution and chi-square or Fisher’s
exact test (for categorical variables).
Primary objective—feasibility
Descriptive statistics will be used to present feasibility
data. The overall study feasibility will be assessed
through the following measures:
– Proportion of people approached (target: 80%):
number of people approached as a proportion of
those meeting clinical eligibility. Reasons for not
approaching will be summarised.
– Proportion of people eligible for the study (target:
65%): number of people meeting all eligibility criteria
as a proportion of those approached. Reasons for
non-eligibility criteria and declining participation
will be summarised.
– Proportion of people enrolled (target: 45%): number
of people completing the baseline questionnaire as a
proportion of those eligible.
– Completion rate (target: 70%): number of
participants completing the end-of-study assessment
as a proportion of those enrolled. It will not be pos-
sible to capture reasons for non-completion as there
will be no interaction between the researcher and
participants once they are enrolled in the study.
The intervention feasibility will be assessed through
the following measures:
– Meditation adherence rate (target: 70%): number of
guided meditations listened to per week over the
total number of meditation sessions scheduled (14
sessions/week)
– Rate of adherence to weekly sessions (target: 50%):
the number of videos viewed over the total number
of videos scheduled per week
– Engagement with the intervention: recording
website navigation patterns and features used (video,
audio and document downloads)
– Content relevance: type of benefits experienced and
aspects of the program most liked and disliked (data
collected through weekly questionnaires)
Secondary objectives—potential efficacy of intervention on
outcome measures
To explore the potential efficacy of the intervention on
any of the secondary outcomes (i.e. fear of cancer recur-
rence, worry, rumination, perceived stress and trait
mindfulness), a linear mixed model will be fitted includ-
ing group (intervention, control), time (pre, post) and
the interaction group by time as fixed effects and partici-
pant as a random effect. We will additionally adjust for
any characteristics or scores showing clear evidence of
imbalance at baseline. All analyses will be undertaken on
an intention-to-treat (ITT) basis, i.e. participants will be
analysed as randomised regardless of adherence.
In addition, potential association between overall
meditation time and the secondary outcome measures
will be assessed in the intervention group. Weekly medi-
tation time will be defined as the maximum between
time collected from Google Analytics and time self-
reported in the weekly questionnaires.
Results of this study will be prepared in accordance
with the CONSORT 2010 statement: extension to ran-
domised pilot and feasibility trials [59].
Data monitoring
Given the short length of the intervention and the length
of the data collection period, an external data monitor-
ing committee is not considered necessary and an in-
terim analysis will not be performed. Nonetheless,
members of the research team are regularly updated
with recruitment status and study progression.
Managing potential risk associated with participation
In the event that a participant becomes upset or dis-
tressed as a result of his/her participation, he/she can
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contact the researcher by email or phone for assistance.
Counselling or other appropriate support will then be
provided by the clinic staff who are not members of the
research team. In addition, participants will receive in
the study information pack contact for external support
services such as Lifeline services or mindhealthconnect.
org.au.
Protocol amendments
Potential protocol modifications will be submitted for
approval by the relevant human research ethics commit-
tees before being implemented.
Dissemination policy
The research team intend to disseminate outcomes from
this study in peer-reviewed journals and at relevant con-
ferences. Participants will have access to study results on
request.
Discussion
This is the first study to address the specific issue of
FCR among people with melanoma using an online
MBI. In the emerging field of online MBIs in oncology,
many fundamental questions specific to the online deliv-
ery mode remain unanswered, including (1) which as-
pects of an online MBI are the most engaging and (2)
can patients learn the basic skills of mindfulness and
benefit from a mindfulness program without interacting
with a trained therapist? This study aims to answer these
questions.
This paper describes the protocol for a pilot RCT with
embedded process evaluations aiming to assess eligibil-
ity, enrolment and retention rates, barriers to recruit-
ment, questionnaire completion rate, and intervention
participation and content relevance. This study will
support the design of a full-scale RCT with a longer
follow-up period, and information collected from the
recruitment process will highlight methodological aspects to
address in the planning of a larger scale study. Participants’
interaction with the website and engagement with the inter-
vention will inform whether this self-managed program has
the capacity to engage participants into learning about and
practising mindfulness skills. This information is collected
on a weekly basis and will allow to address specific aspects
of the program.
Given the positive impact of face-to-face MBIs on can-
cer patients, an online approach has the potential to
provide similar support to individuals unable to attend
face-to-face programs.
Trial status
Recruitment commenced in February 2017 and is ongoing.
Additional files
Additional file 1: SPIRIT 2013 Checklist. (DOC 121 kb)
Additional file 2: The TIDieR (Template for Intervention Description and
Replication) Checklist. (DOCX 31 kb)
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